Evidence map›Paper›PMID 41554678›Full record

ArticleCancer medicine2026

A Real-World Analysis of Outcomes in CIC-Rearranged Sarcomas: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) Study.

Talya Wittmann Dayagi, Hagit Peretz Soroka, Alannah Smrke, Rebecca J Deyell, Xiaolan Feng, Sapna Oberoi, Shantanu Banerji, Jonathan Noujaim, Nicolas Prud'homme, Ramy Saleh and 8 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Talya Wittmann DayagiDivision of Haematology and Oncology, Department of Pediatrics, the Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Hagit Peretz SorokaDivision of Haematology and Oncology, Department of Pediatrics, the Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Alannah SmrkeDepartment of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.
Rebecca J DeyellDivision of Pediatric Hematology/Oncology/BMT, B.C. Children's Hospital and Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0003-3315-4383
Xiaolan FengDivision of Medical Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.
Sapna OberoiDepartment of Pediatrics and Child Health, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID https://orcid.org/0000-0002-6071-0042
Shantanu BanerjiDepartment of Internal Medicine, Rady Faculty of Medicine, CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada.
Jonathan NoujaimDivision of Medical Oncology, Hôpital Maisonneuve Rosemont, University of Montreal, Montreal, Quebec, Canada.
Nicolas Prud'hommeDivision of Medical Oncology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
Ramy SalehDepartment of Medical Oncology, McGill University Health Center, McGill University, Montreal, Quebec, Canada.
Omar Farooq KhanDivision of Medical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID https://orcid.org/0000-0003-4424-5360
Jonathan Willard BushDepartment of Pathology and Laboratory Medicine, BC Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0001-9432-2390
Bilal MarwaDepartment of Pediatrics and Oncology, University of Saskatchewan, Saskatchewan Cancer Agency, Saskatchewan Health Authority, Saskatoon, Saskatchewan, Canada.
Geoffrey WatsonDivision of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-1962-7893
Caroline HollowayDivision of Radiation Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.
Lingxin ZhangDepartment of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Abha Anshu GuptaDivision of Haematology and Oncology, Department of Pediatrics, the Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-0825-5070
Jack BrzezinskiDivision of Haematology and Oncology, Department of Pediatrics, the Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-9475-0077

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCIC-rearranged sarcomas (CRS) are rare tumors predominantly affecting young adults. Despite distinct biology, CRS are often treated like Ewing sarcomas with multi-agent chemotherapy, surgery, and radiotherapy, although the benefits of each remain unclear. We report the impact of treatment on response and survival.

methodsThis retrospective multicenter study included patients diagnosed with CRS between 2002 and 2023. Demographic, treatment, and outcome data were collected. Event-free (EFS) and overall survival (OS) were estimated using Kaplan-Meier analysis; risk factors were assessed via log-rank tests and Cox regression. Treatment response was assessed using RECIST.

resultsAmong 27 patients (median age 21.5 years; range 8-83), 14 (52%) had localized and 12 (44%) metastatic disease (1 unknown). In the localized group, 6 (43%) received chemotherapy (Response: 2 complete, CR; 1 partial, PR; 1 mixed, MR; 1 stable, SD; 1 progressive disease, PD); 5 (36%) died-3 (21%) had received chemotherapy. Among metastatic patients, 10 (83%) received chemotherapy (1 CR, 5 PR, 2 MR, 1 PD); 9 died (one without chemotherapy). Local control was achieved in 12/14 (86%) localized and 7/12 (56%) metastatic patients. Only surgical resection was associated with improved OS (HR 0.13; p < 0.01) and EFS (HR 0.26; p < 0.01), particularly with R0 resection (EFS HR 0.23; p = 0.02). At median follow-up of 18 months, 2-year EFS was 56% vs. 8% (p = 0.02) and OS was 67% vs. 23% (p = 0.02) for localized vs. metastatic disease.

conclusionComplete resection is critical in CRS. Chemotherapy benefit remains uncertain, underscoring the need for improved local control and novel, biology-driven therapies.

Indexed as

Gene RearrangementSarcomaAdolescentAdultAgedAged, 80 and overCanadaChildCombined Modality TherapyFemaleHumansMaleMiddle AgedRepressor ProteinsRetrospective StudiesTreatment OutcomeCIC protein, humanRepressor Proteinsadolescent and young adult oncologychemotherapy responseCIC‐rearranged sarcomaEwing‐like sarcomametastatic sarcomasoft‐tissue sarcomasurgical resection

Identifiers

PMID41554678
PMCPMC12815609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.